Months after the Supreme Court rejected early arguments in the case, a federal judge in Texas ruled Thursday that three Republican-led states will be allowed to move forward with a lawsuit seeking to restrict access to mifepristone. handed down the verdict.
U.S. District Judge Matthew Kacsmalik, who was appointed during President-elect Trump's first term, said the states of Idaho, Missouri and Kansas could intervene and sue in a lawsuit originally brought by a group of anti-abortion activists and doctors. said.
Last year, the Supreme Court dismissed the case, saying there was no legal basis for private parties to challenge access to mifepristone. The justices found that the conservative doctors in the lawsuit had not shown that they had been personally harmed by the government's actions to regulate mifepristone.
In a complaint granted by Kaczmarik, the red states allege that some of the Food and Drug Administration's (FDA) measures to ease access to mifepristone could result in mifepristone leaking across their borders and killing women. They argue that it endangers abortion laws and weakens anti-abortion laws.
States are challenging FDA actions that have eased restrictions on the drug since 2016, such as approving its use during the first 10 weeks of pregnancy and allowing it to be prescribed via telemedicine or by mail.
The Biden administration's Justice Department asked for the lawsuit to be dismissed, arguing that Kansas, Idaho and Missouri lacked legal standing to sue Amarillo, Texas. But Kaczmarik, who ruled against the FDA in 2023 and ordered the drug removed from the market, said those arguments don't apply.
He wrote in his ruling that the FDA and mifepristone manufacturer Danko will have another opportunity to argue for dismissal of the lawsuit. But the timing of the ruling means the Trump administration will take next steps and could decide not to defend the regulations.
President Trump's attorney general nominee, Pam Bondi, was asked during her confirmation hearing by Sen. Cory Booker (D.N.J.) if she intended to defend the FDA's actions in the case, saying more investigation is needed. He did not answer directly. Bondi vowed not to let her personal anti-abortion views influence her actions.
The FDA has repeatedly found that mifepristone is safe and that medication abortion therapy, which includes mifepristone and a second drug, misoprostol, is a safe and effective alternative to surgical abortion. Ta.
The Supreme Court's decision in this case did not address the underlying regulatory or safety issues raised by the plaintiffs, instead deciding only on the merits of the case.
